CompletedPhase 2

A Study to Evaluate the Effect of LCZ696 on Aortic Stiffness in Subjects With Hypertension

Germany, Switzerland, United Kingdom115 participantsStarted 2013-10

Plain-language summary

This was the first evaluation of the effects of LCZ696 on local and regional measures of aortic stiffness in subjects with mild to moderate hypertension and widened pulse pressure. The results of this exploratory study will help to understand the mechanism of action of LCZ696 and used to inform the design of future clinical studies with LCZ696 in subjects with cardiovascular diseases.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Key Inclusion Criteria: * Subjects with essential hypertension, untreated or currently taking antihypertensive therapy Key exclusion Criteria: * women of child bearing potential (WOCBP) if not on highly effective contraception * Malignant or severe hypertension (grade 3 of WHO classification) * History or evidence of a secondary form of hypertension * Transient ischemic cerebral attack (TIA) during the 12 months prior to screening or any history of stroke. * Previous or current diagnosis of heart failure (New York Heart Association Class II-IV).

What they're measuring

Change From Baseline in Ascending Aorta Distensibility at 52 Week

Timeframe: Baseline, 52 weeks

Change From Baseline in Proximal Descending Aorta Distensibility at 52 Weeks

Timeframe: Baseline, 52 weeks

Change From Baseline in Distal Descending Aorta Distensibility at 52 Weeks

Timeframe: Baseline, 52 weeks

Trial details

NCT IDNCT01870739

SponsorNovartis Pharmaceuticals

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2015-06

Results submitted2016-05-31

View on ClinicalTrials.gov More Hypertension trials